Patent ID: 11857617
Assignee: TOPELIA AUST LIMITED (652 771 670)
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 10:
11. The method of claim 1, wherein:
(a) after the first administration of the live, inactivated or attenuated causative agent of the infection, IgM, IgG and/or IgA levels in the individual in need thereof is tested and measured qualitatively and/or quantitatively, and if levels of the measured IgM, IgG and/or IgA are low, a second or additional dosage or administration of the live, inactivated or attenuated causative agent of the infection is given, or
(b) after the first administration of the live, inactivated or attenuated and/or the live, viable or infectious causative agent of the infection levels of the measured IgM, IgG and/or IgA are measured at between about 7 to 21 days, or at 14 and 20 days.